The impact of COVID-19 non-pharmaceutical interventions on notifiable infectious diseases in Poland: a comprehensive analysis from 2014-2022

COVID-19 非药物干预措施对波兰法定传染病的影响:2014-2022 年综合分析

阅读:1

Abstract

INTRODUCTION: The COVID-19 pandemic prompted widespread non-pharmaceutical interventions (NPIs) like lockdowns and masking in Poland (2020–2022), significantly altering pathogen circulation. This created a unique opportunity to study the extended effects of these measures on other communicable diseases, moving beyond short-term observations. AIM: This study aimed to assess how the pandemic and associated NPIs affected the incidence of 17 notifiable infectious diseases in Poland over an extended period, from January 2014 to December 2022. METHODS: Using national surveillance data aggregated monthly, we compared incidence during pandemic years (2020–2022) against pre-pandemic (2014–2018) and baseline (2019) periods. Data were deseasonalized. A negative binomial generalized linear model calculated incidence rate ratios (IRRs) relative to 2019, controlling for confounders. Spearman correlation measured associations between disease incidence, COVID-19 cases, and nine NPIs. RESULTS: From 2020 to 2022, 13 of 17 diseases showed cumulative declines compared to 2014–2019, including whooping cough (peak reduction IRR 0.11 in 2021 vs. 2019), scarlet fever, chickenpox, and mumps. Invasive Streptococcus pneumoniae decreased initially but rebounded in 2022. Conversely, Clostridioides difficile incidence increased significantly (2021 IRR 1.84 vs. 2019). Norovirus, HIV, and syphilis surged later, coinciding with NPI relaxation. Higher NPI stringency generally correlated negatively with respiratory pathogens. CONCLUSION: Long-term observation confirmed that widespread NPIs suppressed many communicable diseases, particularly respiratory infections, beyond SARS-CoV-2. The rebound of several infections upon NPI relaxation suggests potential shifts in population susceptibility. These findings can inform future public health strategies balancing disease control and societal needs, though further research on long-term dynamics is warranted. CLINICAL TRIAL NUMBER: Not applicable.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。